Lunai Bioworks Inc.

NasdaqCM:LNAI Stock Report

Market Cap: US$10.2m

Lunai Bioworks Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Lunai Bioworks.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Biotechs earnings growth25.2%
Revenue growth raten/a
Future return on equityn/a
Analyst coverage

None

Last updatedn/a

Recent future growth updates

No updates

Recent updates

Seeking Alpha • Oct 17

Enochian stock climbs on US patent for oncology platform

Enochian BioSciences (NASDAQ:ENOB) stock rose ~5% on Monday after the company said that it received a U.S. patent for its proprietary cancer treatment platform which could potentially be used to induce life-long remission. Preclinical animal and laboratory studies of the company’s product candidate to treat pancreatic cancer in humanized mice model of hu-BLT (ENOB-DC-11) have shown positive results, the company added. "We are incredibly excited to have been awarded this patent for Enochian’s allogeneic cell and gene therapy cancer treatment platform, especially following promising early study results," said Enochian's CEO Mark Dybul. Enochian noted that if results remain positive, it will potentially submit a pre-IND application to the FDA by early- to mid-2023, followed by IND submission and human trials planned for the end of 2023 or early 2024. The company hopes to expand its oncology treatment platform to product candidates which could include triple-negative breast cancer, glioblastoma and/or kidney cancer.
Seeking Alpha • Jul 01

Enochian BioSciences discovers two sets of altered animal data in two of its studies

After an internal review of its scientific data, Enochian BioSciences (NASDAQ:ENOB) has discovered that a former scientific advisor had altered and falsified two sets of animal data before the company's scientists could review it. "One data set was for an inhaled COVID-19 treatment study while the other was for a (hepatitis B virus) therapy study," the biotech company said in a statement on Friday. As a result of its discovery, the company said it would initiate legal action against the former scientific advisor, Serhat Gumrukçu. ENOB said that its investigation verified certain data from the COVID-19 and (hepatitis B virus) pipelines. "The company is evaluating its internal controls regarding the review and verification of external scientific data and will modify as appropriate," ENOB said. ENOB stock -4.7% to $1.84 in aftermarket trading.
Analysis Article • Jun 28

Is Enochian Biosciences (NASDAQ:ENOB) Using Debt Sensibly?

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...
Analysis Article • Feb 20

Enochian Biosciences (NASDAQ:ENOB) Has Debt But No Earnings; Should You Worry?

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Analysis Article • Oct 30

Enochian Biosciences (NASDAQ:ENOB) Has Debt But No Earnings; Should You Worry?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Seeking Alpha • Jun 26

Enochian Biosciences: A Follow Through For An HIV Cure

ENOB announced on June 14, 2021, that it has entered into a 29 million registered direct offering, improving its sustainability. Its Pre-IND request for a potential HIV cure has been approved by the FDA. On June 21, 2021, the company announced that they acquired an exclusive license for an Inhaled Treatment and Prevention Technology to potentially treat and prevent all variants of the Coronavirus. ENOB is expected to burn more cash in the coming years, but on the brighter side, institutions backed them up as they are starting to generate good results for their investors.
Analysis Article • Feb 14

Do Insiders Own Lots Of Shares In Enochian Biosciences, Inc. (NASDAQ:ENOB)?

If you want to know who really controls Enochian Biosciences, Inc. ( NASDAQ:ENOB ), then you'll have to look at the...

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Lunai Bioworks has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

NasdaqCM:LNAI - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
3/31/20260-128-5-5N/A
12/31/2025N/A-126-6-6N/A
9/30/2025N/A-131-7-7N/A
6/30/2025N/A-178-8-8N/A
3/31/2025N/A-67-9-8N/A
12/31/2024N/A-126-10-10N/A
9/30/2024N/A-123-10-10N/A
6/30/2024N/A-88-11-11N/A
3/31/2024N/A-96-11-11N/A
12/31/2023N/A-41-12-11N/A
9/30/2023N/A-41-12-12N/A
6/30/2023N/A-40-12-12N/A
3/31/2023N/A-107-13-13N/A
12/31/2022N/A-109-12-12N/A
9/30/2022N/A-111-13-13N/A
6/30/2022N/A-113-16-16N/A
3/31/2022N/A-41-26-26N/A
12/31/2021N/A-38-25-25N/A
9/30/2021N/A-35-23-23N/A
6/30/2021N/A-27-21-21N/A
3/31/2021N/A-13-10-10N/A
12/31/2020N/A-11-11-11N/A
9/30/2020N/A-10-12-11N/A
6/30/2020N/A-11-11-10N/A
3/31/2020N/A-6-11-10N/A
12/31/2019N/A-7N/A-9N/A
9/30/2019N/A-22N/A-9N/A
6/30/2019N/A-18N/A-9N/A
3/31/2019N/A-21N/A-8N/A
12/31/2018N/A-21N/A-7N/A
9/30/2018N/A-6N/A-6N/A
6/30/2018N/A-6N/A-4N/A
3/31/2018N/A-4N/A-3N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if LNAI's forecast earnings growth is above the savings rate (3.5%).

Earnings vs Market: Insufficient data to determine if LNAI's earnings are forecast to grow faster than the US market

High Growth Earnings: Insufficient data to determine if LNAI's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if LNAI's revenue is forecast to grow faster than the US market.

High Growth Revenue: Insufficient data to determine if LNAI's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if LNAI's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/26 10:38
End of Day Share Price 2026/05/22 00:00
Earnings2026/03/31
Annual Earnings2025/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Lunai Bioworks Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.